Felicetto Ferrara

8PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò

|Sep 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Fabio Guolo, Luana Fianchi, Maria Paola Martelli

|May 09, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.

Massimo Breccia, Antonella Russo Rossi, Valentina Giai

|Mar 22, 2025
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Cristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi

|May 28, 2021
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.

Alfonso Piciocchi, Monica Messina, Loredana Elia

|Aug 11, 2020
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.

Anna Candoni, Davide Lazzarotto, Felicetto Ferrara

Pageof 2

Frequent Collaborators

3 joint publications

Francesco Albano

2 joint publications

Massimo Breccia

2 joint publications

Erika Borlenghi

2 joint publications

Federico Lussana